Hawaii Parkinson's & Movement Center awarded Hawaii's First Research on Lewy Body Dementia to Study Remlifanserin selective agonist of 5HT2A



More than 1 million people in the United States are diagnosed with Lewy Body Dementia (LBD), which is one of the most common forms of dementia. It is a progressive disease, meaning symptoms start slowly and worsen over time. LBD can lead to problems with thinking, movement, behavior, and mood. Visual hallucinations tend to happen early on. Lewy bodies, which are a microscopic aggregation of a specific protein (α-synuclein) are noted in the brain.



ACP-204 is an investigational drug being studied for the treatment of psychosis in Alzheimer's and LBD. The research focuses on its potential to treat hallucinations and delusions associated with LBD, for which there is a significant unmet medical need.

ACP-204, also known as remlifanserin, is a drug in development by Acadia Pharmaceuticals for the treatment of dementia-related psychosis. This includes psychosis associated with both Alzheimer's disease and Lewy body dementia. It is a follow-up compound to Acadia's existing drug, pimavanserin (Nuplazid). ACP-204 functions as a potent and selective inverse agonist of the 5-HT2A serotonin receptor. By blocking the activity of this specific receptor, it is designed to treat the hallucinations and delusions that can occur with dementia.

Compared to pimavanserin, ACP-204 has been shown to be more potent and selective. Acadia designed it to potentially have an improved profile, including a shorter half-life and a reduced risk of QT prolongation, a heart-rhythm abnormality that can be a side effect of some drugs.

The study is multicenter, randomized, double-blind, and placebo-controlled. Participants receive either 30 mg or 60 mg of ACP-204 or a placebo. The main goal is to measure the change in hallucinations and delusions using the Scale for the Assessment of Positive Symptoms (SAPS-H+D).

Eligibility: Participants must be 55-85, meet specific criteria for LBD, have psychosis symptoms,

"Our team of neurologists, neuroscience specialists and researchers in Hawaii cannot be more proud to be part of this ground breaking research to develop for LBD" says Kore Liow, MD, Principal Investigator, Neurologist & Neuroscience Chair at Hawaii Pacific Neuroscience & Clinical Professor of Medicine (Neurology), University Hawaii JABSOM

CLINICAL TRIALS

For more information, See NIH Info or please contact: Hawaii Parkinson's Disease Center & Hawaii Parkinson's Research Unit 2230 Liliha Street #104, HONOLULU, HI 96817
Research Hotline (808) 564-6141 info@HawaiiNeuroscience.com